New Approaches for Incorporating Genetic Diversity into Toxicity Testing
- NIH
- Jun 3, 2020
- 1 min read
Our multi-prong approach is expected to de-risk drug failure in mammalian AD models. In summary, we will use a novel NemaLife technology to identify a subset of pharmacological longevity interventions will exert neuroprotection against AD-relevant stresses.

Comentarios